EN DE
Watch Chiang Mai Ram Medical Business Public Company Limited for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Chiang Mai Ram Medical Business Public Company Limited (CMR) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Chiang Mai Ram Medical Business Public Company Limited stock THB 2.42, price THB 1.20, upside +101.7%, quality 55 out of 100. Rating: strongly undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TH · ISIN TH0432010Z05

CM Chiang Mai Ram Medical Business Public Company Limited logo Thin data Nov 19, 2026

Chiang Mai Ram Medical Business Public Company Limited

CMR · BK

Cheap (50% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Follow free in the weekly email
Fair value 2.42 THB · Strongly undervalued 
Highly profitable · 95.5% net margin (TTM) 
Low debt 
Ranks above peers (10/15) 
Costs just 2 times its yearly profit. 
Quality 55/100 
Expensive Growth (revenue 5y +6.1 %/yr in THB) 
8.7% dividend yield · Watch coverage
Wide moat 70/100 · thin data
Changed on Nov 14: THB 3.53 → THB 2.42 
Falling price (downtrend) 
Negative free cash flow over the last twelve months 
Thin data 
⚠ Small free float
Watch Chiang Mai Ram Medical Business Public Company Limited for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.97 THB 0.9700 THB Fair Value 2.42 THB Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 19, 2026.

How to read this chart

60‑month range 0.9700 THB – 2.97 THB · fair‑value band 1.82 THB – 3.03 THB · the 1.20 THB price screens below the 2.42 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 19, 2026.

Follow Chiang Mai Ram Medical Business Public Company in your weekly email

Every Wednesday you see whether Chiang Mai Ram Medical Business Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Chiang Mai Ram Medical Business Public Company Limited provides medical services in Thailand. It operates hospitals under the Lanna Hospital name, as well as engages in the sales of medicine and medical supplies. The company was founded in 1974 and is headquartered in Chiang Mai, Thailand.

Show moreShow less

Chiang Mai Ram Medical Business Public Company Limited is a subsidiary of Vibhavadi Medical Center Public Company Limited.

Stock analysis

Chiang Mai Ram Medical Business Public Company Limited (CMR) currently trades at 1.20 THB, while our model-based Fair Value estimate is 2.42 THB, implying the stock looks roughly 50% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 11.27 THB per share, and 15 of the 21 models we run sit above the 1.20 THB price.

Bear case: the Asset-Based group reads lowest at 0.7000 THB, and 6 of the 21 models stay below the price. Data coverage for this calculation is low.

Scenario range: 1.82 THB (bear) to 3.03 THB (bull), the price of 1.20 THB sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Chiang Mai Ram Medical Business Public Company Limited reported revenue of 2.5B THB in FY2025 versus 4.2B THB in FY2021, a compound −12.2%/yr. Reported net income was 2.4B THB in FY2025, compounding +70.1%/yr from FY2021.

Key figures

Market cap 4.9B THB (≈ $144M) Micro · P/E ratio 2.0 · P/S ratio 1.93 · EPS (TTM) 0.6000 THB · Dividend yield 8.7% · Net margin 95.5% · Return on equity 50.8% · Return on assets (EBIT) 4.2% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 70 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at 102%, CMR screens cheaper than that median.

Fair Value models

Bear 1.82 THB Fair Value 2.42 THB Bull 3.03 THB
Price 1.20 THB · Upside +101.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (0.4389 THB per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings 4.99 THB 7.72 THB 11.51 THB 76
FCF DCF 0.0300 THB 0.1100 THB 0.2100 THB 74
5Y EBITDA Exit 0.6700 THB 1.41 THB 2.35 THB 72
All 22 models by family
DCF Models
FCF DCF 0.0300 THB 0.1100 THB 0.2100 THB 74
Owner Earnings 4.99 THB 7.72 THB 11.51 THB 76
5Y Revenue Exit 0.0700 THB 0.2000 THB 0.3700 THB 68
5Y EBITDA Exit 0.6700 THB 1.41 THB 2.35 THB 72
5Y P/E Exit 5.08 THB 10.37 THB 16.44 THB 69
10Y Revenue Exit 0.0500 THB 0.1500 THB 0.3000 THB 62
10Y EBITDA Exit 0.3800 THB 0.8800 THB 1.66 THB 64
10Y P/E Exit 2.81 THB 6.31 THB 11.34 THB 61
Earnings-Based
Graham-Dodd 4.09 THB 18.06 THB 24.73 THB 64
Lynch FV 6.14 THB 8.77 THB 11.40 THB 61
PEG = 1.0 6.14 THB 8.77 THB 11.40 THB 57
Dividend Discount
Gordon GGM 2.04 THB 3.34 THB 4.26 THB 69
DDM Multi-Stage 2.04 THB 3.20 THB 3.60 THB 67
Multiples
P/E Multiple 9.91 THB 13.22 THB 16.52 THB 63
P/S Multiple 1.61 THB 2.15 THB 2.68 THB 58
P/B Multiple 1.82 THB 2.42 THB 3.03 THB 55
EV/EBIT n/a n/a 0.0500 THB 61
EV/EBITDA 0.9500 THB 1.41 THB 1.87 THB 66
Asset-Based
NCAV (Graham) 0.5300 THB 0.7000 THB 1.05 THB 54
Growth DCF
Growth DCF 0.0300 THB 0.0900 THB 0.1800 THB 72
Economic Profit
Residual Income 2.58 THB 3.53 THB 6.51 THB 72
Growth Earnings
Growth-Adj P/E 7.89 THB 11.27 THB 14.66 THB 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 65
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 42
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 93
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
What shareholders gained per year (last 5 years), in THB (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+56.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+47.4%
Dividend (yield on the price)8.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.52.6% vs 20.1%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 4%
2025 sits 1,016% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.

Watch CMR, get fair value alerts →

Compare Chiang Mai Ram Medical Business Public Company Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 250 stocks

Beats the industry median on 10/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside +101.7% · Top 25%
Profitability
Return on equity (12 months) 50.8% · Top 25%
Return on assets 30.0% · Top 25%
Net margin (12 months) 95.5% · Top 25%
Operating margin (12 months) 4.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −0.5% · Bottom 25%
Dividend yield (12 months) 8.7% · Top 25%
Balance sheet
Debt / equity 0.19× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 2.0× · Cheapest 25%
P/B 1.09× · Cheaper than median
P/S (12 months) 1.93× · Pricier than median
Price / free cash flow (fiscal year) 358.9× · Priciest 25%
EV/EBITDA 11.4× · Pricier than median
PEG 0.04× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 36
FUTURE (revenue growth)0 · sector 33
PAST (return on equity)100 · sector 32
HEALTH (low debt)90 · sector 90
DIVIDEND (yield)100 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $20.95 $45.53 +117% vs CMR
DaVita Inc DVA $161.79 $218.90 +35% vs CMR
Aier Eye Hospital Group 300015 ¥9.02 ¥10.88 +21% vs CMR
HCA Healthcare, Inc HCA $476.35 $547.34 +15% vs CMR
Tenet Healthcare Corporation THC $271.34 $279.20 +3% vs CMR
The Ensign Group ENSG $182.98 $140.09 −23% vs CMR
Encompass Health Corporation EHC $134.93 $94.81 −30% vs CMR
Fresenius SE FRE €51.78 €34.77 −33% vs CMR
Dr. Sulaiman Al Habib Medical Services Group 4013 207.90 SAR 109.45 SAR −47% vs CMR
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,738 ₹2,908 −67% vs CMR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Chiang Mai Ram Medical Business Public Company Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Chiang Mai Ram Medical Business Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/CMR

Frequently asked questions

Is Chiang Mai Ram Medical Business Public Company Limited (CMR) overvalued or undervalued?
As of Nov 19, 2026, our model estimates a fair value of 2.42 THB versus a price of 1.20 THB, about +102% upside (undervalued).
What is the fair value of CMR?
Our model-based fair value for Chiang Mai Ram Medical Business Public Company Limited is 2.42 THB (as of Nov 19, 2026), built from audited fundamentals. The current price: 1.20 THB.
What is the quality score of CMR?
Chiang Mai Ram Medical Business Public Company Limited has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chiang Mai Ram Medical Business Public Company Limited (CMR)?
We do not set a price target; the yardstick is the fair value of 2.42 THB (as of Nov 19, 2026) from 22 valuation models. Cautious scenario 1.82 THB, optimistic scenario 3.03 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Chiang Mai Ram Medical Business Public Company Limited stock forecast for 2026?
Our models put fair value at 2.42 THB, about +102% upside versus a price of 1.20 THB (undervalued). Cautious scenario 1.82 THB, optimistic scenario 3.03 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
Chiang Mai Ram Medical Business Public Company Limited reported trailing-twelve-month revenue of about 2.5B THB (latest available figure, as of Nov 19, 2026).
Does Chiang Mai Ram Medical Business Public Company Limited pay a dividend?
Chiang Mai Ram Medical Business Public Company Limited currently shows a dividend yield of 8.67% relative to its recent price (as of Nov 19, 2026).
How much is the dividend of Chiang Mai Ram Medical Business Public Company Limited (CMR) and when is the ex-dividend date?
Chiang Mai Ram Medical Business Public Company Limited pays a dividend of 0.104 THB per share a year, a dividend yield of 8.7%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2003. The payout ratio is 17.3% of earnings. Free cash flow covers the dividend 0.03 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Chiang Mai Ram Medical Business Public Company Limited (CMR)?
For today's price to be fair in a discounted-cash-flow model, Chiang Mai Ram Medical Business Public Company Limited would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 7.4 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 19, 2026.
What discount rate (WACC) does the fair value of CMR use?
Our models discount Chiang Mai Ram Medical Business Public Company Limited at 13.1 %: a base by market capitalisation (micro), damped by beta 0.26, country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Chiang Mai Ram Medical Business Public Company Limited that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has Chiang Mai Ram Medical Business Public Company Limited (CMR) delivered so far?
Over the past 5 years revenue at Chiang Mai Ram Medical Business Public Company Limited shrank 7.4 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Chiang Mai Ram Medical Business Public Company Limited (CMR) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Chiang Mai Ram Medical Business Public Company Limited (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The free-cash-flow yield on the price is 0.28 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Chiang Mai Ram Medical Business Public Company Limited produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chiang Mai Ram Medical Business Public Company Limited it is 2.42 THB per share (as of Nov 19, 2026), against a price of 1.20 THB. It is the blended result of 22 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Chiang Mai Ram Medical Business Public Company Limited stock overvalued or undervalued in 2026?
As of Nov 19, 2026, CMR trades below its calculated fair value: price 1.20 THB, fair value 2.42 THB, a gap of about +102% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CMR?
No. The price is what the market pays today (1.20 THB); the fair value is what the company's own numbers justify (2.42 THB). For Chiang Mai Ram Medical Business Public Company Limited the two are 1.22 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Chiang Mai Ram Medical Business Public Company Limited worth?
The market values Chiang Mai Ram Medical Business Public Company Limited at about 4.9B THB (market capitalisation, as of Nov 19, 2026). Per share that is 1.20 THB; our models calculate a fair value of 2.42 THB per share.
What do the bullish and bearish scenarios say about CMR?
Our models span a range for Chiang Mai Ram Medical Business Public Company Limited: cautious scenario 1.82 THB, base 2.42 THB, optimistic 3.03 THB per share (as of Nov 19, 2026, price 1.20 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CMR?
Chiang Mai Ram Medical Business Public Company Limited trades at a price-to-earnings ratio of 2.0 (as of Nov 19, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2.42 THB is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 33.9. Other multiples: PEG 0.0, P/B 1.1, P/S 1.9, EV/EBITDA 11.4.
What is the PEG ratio of CMR?
The PEG ratio of Chiang Mai Ram Medical Business Public Company Limited is 0.04 (P/E divided by earnings growth, as of Nov 19, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
Balance-sheet figures for Chiang Mai Ram Medical Business Public Company Limited (as of Nov 19, 2026): return on equity 50.8%, debt of 0.19 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is CMR from its 52-week high?
Chiang Mai Ram Medical Business Public Company Limited trades at 1.20 THB, about 20% below its 52-week high of 1.50 THB and at the low of 1.20 THB (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 2.42 THB is for.
Which stocks are comparable to Chiang Mai Ram Medical Business Public Company Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chiang Mai Ram Medical Business Public Company Limited stock attractive at the current price?
The data as of Nov 19, 2026: price 1.20 THB, calculated fair value 2.42 THB (+102%), Quality Score 55/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CMR calculated?
We run Chiang Mai Ram Medical Business Public Company Limited through 22 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2.42 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Chiang Mai Ram Medical Business Public Company Limited currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The closing price on Nov 19, 2026 was 1.20 THB. Our model-based fair value is 2.42 THB, about +102% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chiang Mai Ram Medical Business Public Company Limited right now?
The price is below even our cautious bear case (1.82 THB). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Chiang Mai Ram Medical Business Public Company Limited (CMR) come from?
Earnings per share at Chiang Mai Ram Medical Business Public Company Limited grew 9.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.1 %, EBIT margin −8.6 %, tax rate +2.2 %, residual (interest, one-offs) +13.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Chiang Mai Ram Medical Business Public Company Limited

How large is the market capitalisation of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The market capitalisation of Chiang Mai Ram Medical Business Public Company Limited is 4.9B THB (≈ $144M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The price-to-sales ratio of Chiang Mai Ram Medical Business Public Company Limited is 1.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
Earnings per share at Chiang Mai Ram Medical Business Public Company Limited are 0.6000 THB (price ÷ EPS = P/E 2.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The dividend yield of Chiang Mai Ram Medical Business Public Company Limited is 8.7% (payout 17.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The net margin of Chiang Mai Ram Medical Business Public Company Limited is 95.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The return on equity (ROE) of Chiang Mai Ram Medical Business Public Company Limited is 50.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
On an EBIT basis the return on assets of Chiang Mai Ram Medical Business Public Company Limited is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chiang Mai Ram Medical Business Public Company Limited (CMR)?
The operating margin of Chiang Mai Ram Medical Business Public Company Limited is 4.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chiang Mai Ram Medical Business Public Company Limited (CMR)?
Revenue at Chiang Mai Ram Medical Business Public Company Limited is down 0.5% versus a year earlier (3y avg +8.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chiang Mai Ram Medical Business Public Company Limited (CMR)?
Earnings per share at Chiang Mai Ram Medical Business Public Company Limited are down 59.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Chiang Mai Ram Medical Business Public Company Limited (CMR) carry?
The net debt of Chiang Mai Ram Medical Business Public Company Limited is 1.7B THB (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Chiang Mai Ram Medical Business Public Company Limited in the live analysis

One click puts Chiang Mai Ram Medical Business Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.